Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

Group 1 - The call is led by Scott Smith, CFO of Ascendis Pharma, along with other key executives including Jan Moller Mikkelsen and Aimee Shu [2] - The presentation includes forward-looking statements related to the development of TransCon CNP and TransCon Growth Hormone combination treatment, as well as pipeline candidates [3]